Immuno-Oncology | Specialty

Lead Researcher Discusses Anti-PD-L1 Agent Avelumab in Ovarian Cancer

August 18th 2015

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

Atezolizumab Again Achieves Phase II Success in PD-L1-Positive Lung Cancer

August 17th 2015

Atezolizumab met the primary endpoint of objective response in PD-L1–positive patients with advanced non–small cell lung cancer in the phase II BIRCH trial.

Immunotherapy May Hold the Key to Attacking HPV-Associated Cancers

August 14th 2015

An improved understanding of the natural history of HPV, its interaction with the host immune system, and the distinct molecular alterations underlying HPV-positive cancers, are fueling development of new drugs, particularly immunotherapies geared toward generating an HPV-specific immune response.

FDA Delays Decision on Frontline Nivolumab in Melanoma

August 12th 2015

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.

Novel Immunotherapeutic Agent Shows Benefit in Ovarian Cancer

August 10th 2015

Premal H. Thaker, MD, discusses EGEN-001 in combination with pegylated liposomal doxorubicin and the potential of immunotherapy agents in ovarian and other similar cancers.

Biomarker Chase Continues With Checkpoint Agents in Lung Cancer

August 10th 2015

Achieving true precision medicine with PD-1/PD-L1 agents in NSCLC will only come from biomarker-driven frontline regimens delivered to the right patients.

Role of Anti-PD-1/PD-L1 Immunotherapy in Cancer

August 6th 2015

Immunotherapy for the treatment of cancer has evolved alongside our improved understanding of the immune system.

Pembrolizumab Demonstrates Potential of Immunotherapy in Gastric Cancer

August 5th 2015

Yung-Jue Bang, MD, PhD, discusses how the results of the KEYNOTE-012 study demonstrate the potential of immunotherapy in treating gastric cancer.

Role of Anti-PD-1/PD-L1 Immunotherapy in Bladder Cancer

August 3rd 2015

Results from clinical trials demonstrate that immunotherapy is ready to take center stage in the fight against bladder cancer.

Immune Checkpoint Combination Strategies Evolving in NSCLC

August 1st 2015

A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.

Translational Advances Deliver Precision Medicine to NSCLC

July 31st 2015

Paul Bunn, MD, discussed the latest translational advances in NSCLC at the 2015 International Lung Cancer Congress.

ASCO 2015: All About PD-1, But What's Next?

July 29th 2015

At the 2015 ASCO Annual Meeting, we witnessed an extraordinary explosion into the general oncology consciousness of the Programmed Death-1: Programmed Death Ligand-1 axis and drugs that target that interaction.

Anti-PD-L1 Immunotherapy: Emerging Clinical Data

July 27th 2015

Emerging clinical data suggest that targeted immunotherapy in cancer will become an integral part of the clinical management strategy for solid tumors.

Pembrolizumab Benefit in SCCHN Confirmed in Expansion Study

July 24th 2015

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.

Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers

July 24th 2015

A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.

Dr. Luis A. Diaz, Jr. on Pembrolizumab For MMR-Deficient Colorectal Cancer

July 23rd 2015

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).

Dr. Infante on Avelumab's Potential in Ovarian Cancer

July 22nd 2015

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

European Commission Approves Pembrolizumab for Advanced Melanoma

July 22nd 2015

The European Commission has approved the PD-1 inhibitor pembrolizumab as a treatment for adult patients with unresectable or metastatic melanoma in the first-line and previously treated settings.

A Focus on Pathways: Evolving Role of Oncolytic Immunotherapy in Melanoma

July 21st 2015

Advances in the field of immunotherapy and targeted therapy have brought about new recommendations for patients with melanoma.

Nivolumab Improves Survival in Phase III RCC Trial

July 20th 2015

The phase III CheckMate-025 trial has been halted after an independent panel determined that nivolumab improved overall survival versus everolimus in patients with advanced renal cell carcinoma.

NEXT PAGE
PREVIOUS PAGE